Kolltan Pharmaceuticals licenses anti-KIT antibodies from University of Toronto Pharmaceutical Business Review Kolltan Pharmaceuticals, a privately held biopharmaceutical company, has signed a licensing agreement with the University of Toronto for anti-KIT receptor tyrosine kinase antibodies identified in the laboratories of Dr Sachdev Sidhu at the University ... |
